首页> 外文期刊>The Journal of Urology >Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma.
【24h】

Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma.

机译:胰岛素样生长因子I受体的表达与透明细胞肾细胞癌患者的生存率。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: The development of scoring systems that combine pathological and clinical characteristics of clear cell renal cell carcinoma (CC-RCC) have improved outcome prediction in patients with CC-RCC. However, these scoring systems represent surrogate markers of the underlying molecular mechanisms of tumor aggressiveness and provide no tangible targets for potential therapy. As such, there is a need to identify molecular prognostic markers and potential targets of therapy for CC-RCC. Recent studies suggest that the insulin-like growth factor-I receptor (IGF-IR) may have prognostic value for patients with CC-RCC. MATERIALS AND METHODS: Using a large, clinic based cohort of 280 patients who had CC-RCC treated with radical nephrectomy, we tested the hypothesis that the immunohistochemical detection of IGF-IR expression in CC-RCC is associated with poorer cancer specific survival. RESULTS: Kaplan-Meier analysis suggested that patients with IGF-IR positive CC-RCC experienced significantly decreased cancer specific survival than those with IGF-IR negative CC-RCC. The difference in survival was apparent within 2 years after surgery and it remained throughout followup. Based on a Cox proportional hazard model adjusting for age and sex patients with tumors that showed IGF-IR expression had a 70% increased risk of death due to CC-RCC than patients who had tumors without IGF-IR expression (HR = 1.7, 95% CI 1.2 to 2.6). The risk of CC-RCC death increased in individuals with greater than 50% IGF-IR expression (HR = 1.9, 95% CI 1.2 to 3.0). Adjustment for the Mayo Clinic Stage, Size, Grade and Necrosis Score attenuated the risk estimates but did not completely explain the association. CONCLUSIONS: Evidence from this investigation is consistent with laboratory data suggesting that IGF-IR expression is associated with CC-RCC survival and could potentially represent a molecular avenue for therapeutic intervention.
机译:目的:结合透明细胞肾细胞癌(CC-RCC)的病理和临床特征的评分系统的开发,改善了CC-RCC患者的预后。然而,这些评分系统代表了肿瘤侵袭性的潜在分子机制的替代标记,并没有提供潜在治疗的明确目标。因此,需要鉴定CC-RCC的分子预后标志物和治疗的潜在靶标。最近的研究表明,胰岛素样生长因子-I受体(IGF-IR)对于CC-RCC患者可能具有预后价值。材料与方法:我们使用一个基于临床的大型队列研究,对280例接受了根治性肾切除术治疗的CC-RCC患者进行了研究,我们检验了以下假设:CC-RCC中IGF-IR表达的免疫组织化学检测与较差的癌症特异性生存相关。结果:Kaplan-Meier分析表明,与IGF-IR阴性CC-RCC相比,IGF-IR阳性CC-RCC的患者的癌症特异性生存率显着降低。术后2年内生存率差异明显,并且在整个随访过程中一直存在。基于Cox比例风险模型,该模型针对患有肿瘤且显示IGF-IR表达的年龄和性别患者调整了CC-RCC导致的死亡风险比没有IGF-IR表达的肿瘤患者增加了70%(HR = 1.7,95 %CI 1.2至2.6)。大于50%IGF-IR表达的个体发生CC-RCC死亡的风险增加(HR = 1.9,95%CI 1.2至3.0)。梅奥临床分期,大小,等级和坏死评分的调整减弱了风险估计,但并未完全解释这种关联。结论:这项研究的证据与实验室数据一致,提示IGF-1R的表达与CC-RCC的存活有关,并可能代表治疗手段的分子途径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号